European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor

The majority of patients with chronic myeloid leukemia in chronic phase gain substantial benefit from imatinib but some fail to respond or lose their initial response. In 2006, the European LeukemiaNet published recommendations designed to help identify patients responding poorly to imatinib. Patien...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Blood
Main Authors: Marin, David, Milojkovic, Dragana, Olavarria, Eduardo, Khorashad, Jamshid S., de Lavallade, Hugues, Reid, Alistair G., Foroni, Letizia, Rezvani, Katayoun, Bua, Marco, Dazzi, Francesco, Pavlu, Jiri, Klammer, Matthias, Kaeda, Jaspal S., Goldman, John M., Apperley, Jane F.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2008
Assuntos:
Clinical Trials and Observations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6143157/
https://ncbi.nlm.nih.gov/pubmed/18716134
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-06-162388
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares